INDV (Indivior Pharmaceuticals, Inc. Common Stock) Stock Analysis - News
Indivior Pharmaceuticals, Inc. Common Stock (INDV) is a publicly traded Healthcare sector company. As of May 20, 2026, INDV trades at $38.04 with a market cap of $4.32B and a P/E ratio of 22.16. INDV moved +2.91% today. Year to date, INDV is +3.53%; over the trailing twelve months it is +216.69%. Its 52-week range spans $7.33 to $41.00. Analyst consensus is strong buy with an average price target of $50.67. Rallies surfaces INDV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in INDV news today?
Monthly Injectable Buprenorphine Linked to 3.5–8.1x Lower Relapse Risk and 62% Fewer Infections: Two retrospective real-world studies show adherence to monthly injectable buprenorphine is linked to 3.5–8.1x lower opioid relapse risk versus other MOUD and a 62% reduction in bacteremia incidence. Extended-release buprenorphine patients also had 56% fewer inpatient, 22% fewer emergency, and 21% fewer outpatient visits over six months.
Monthly Injectable Buprenorphine Linked to 3.5–8.1x Lower Relapse Risk and 62% Fewer Infections: Two retrospective real-world studies show adherence to monthly injectable buprenorphine is linked to 3.5–8.1x lower opioid relapse risk versus other MOUD and a 62% reduction in bacteremia incidence. Extended-release buprenorphine patients also had 56% fewer inpatient, 22% fewer emergency, and 21% fewer outpatient visits over six months.
Does Rallies summarize INDV news?
Yes. Rallies summarizes INDV news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is INDV research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INDV. It does not provide personalized investment advice.
